Bristol Myers Squibb Doubles Down on AI with NVIDIA SuperPOD Expansion
Event summary
- Bristol Myers Squibb (BMY) is deploying an NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems, creating the most powerful single-owned AI infrastructure in life sciences.
- The new system delivers up to ten times greater performance per megawatt than its predecessor, enabling larger and more sophisticated AI workloads without proportional energy increases.
- This expansion builds on nearly three years of collaboration between BMS and NVIDIA, supporting AI-driven scientific programs across oncology, hematology, cardiovascular, immunology, and neuroscience.
- BMS's AI agents are already automating target identification and validation, saving scientists weeks of manual work and informing experimental design through its 'Predict First' approach.
The big picture
Bristol Myers Squibb's investment in AI infrastructure underscores the growing importance of computational power in drug discovery. As biopharmaceutical companies increasingly rely on AI to automate and optimize research processes, BMS's strategic partnership with NVIDIA positions it at the forefront of this technological shift. The expansion of its compute capabilities reflects a broader industry trend toward hybrid intelligence models, where AI augments human expertise to improve decision-making and accelerate innovation.
What we're watching
- AI Integration Scale
- How BMS will scale its AI-powered research across multiple therapeutic areas and whether the new infrastructure can support the growing complexity of its programs.
- Hybrid Intelligence Model
- The effectiveness of BMS's hybrid intelligence model, where AI co-scientists and human researchers operate in close coordination, in accelerating drug discovery and development.
- Competitive Advantage
- Whether BMS can maintain a competitive edge through its proprietary AI models trained on decades of scientific data, particularly as other biopharmaceutical companies invest in similar technologies.